A Review of Tisotumab Vedotin-tftv in Recurrent or Metastatic Cervical Cancer

202224 citationsReview

Authors

Nathan Heitz · Jackson-Madison County General Hospital

Abstract

TV is the first Food and Drug Administration-approved TF-directed ADC. With a manageable safety profile and promising anticancer activity, TV warrants consideration as a novel targeted agent for the treatment of recurrent or metastatic cervical cancer. Further studies are required to determine the optimal place in therapy for TV.

Topics & Keywords

HER2/EGFR in Cancer Research Sarcoma Diagnosis and Treatment Lymphoma Diagnosis and Treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Annals of Pharmacotherapy

Volume 57, Issue 5, pp. 585-596

DOI: 10.1177/10600280221118370

Field-Weighted Citation Impact: 2.51